Literature DB >> 7512007

Human anti-fibronectin antibodies in systemic lupus erythematosus: occurrence and antigenic specificity.

M S Atta1, R J Powell, N D Hopkinson, I Todd.   

Abstract

Sera from patients with connective tissue diseases exhibit autoantibodies to a spectrum of extracellular matrix proteins. Antibodies binding to solid phase bovine fibronectin (Fn) were investigated by ELISA in patients with systemic lupus erythematosus (SLE). Sera showing binding of 2 s.d. above the mean of the normal human control were considered positive and 43/150 SLE sera (28.7%) demonstrated such binding. These antibodies were mainly IgG and IgA as determined by isotype-specific ELISA. Specificity studies on selected positive sera revealed that binding was inhibited by preincubation with soluble Fn, but not with thyroglobulin or type 1 collagen. The binding was demonstrated not to be related to interactions with rheumatoid factor, complement components or immune complexes. Additional studies to determine which Fn fragment is bound by naturally occurring anti-Fn antibodies demonstrated that the binding was predominantly to the 30-kD collagen binding domain (CBD) of Fn molecule. Inhibition studies using 120-kD, 40-kD and 30-kD Fn fragments confirmed that this binding site was the 30-kD CBD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512007      PMCID: PMC1534551          DOI: 10.1111/j.1365-2249.1994.tb06223.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Morphea with high titer of fibronectin antibodies.

Authors:  C M Stefanato; A Gorkiewicz-Petkow; M Jarzabek-Chorzelska; S Jablonska; T Chorzelski
Journal:  Int J Dermatol       Date:  1992-03       Impact factor: 2.736

2.  Autoimmunity to collagen: a shared feature of psoriatic and rheumatoid arthritis.

Authors:  D E Trentham; G M Kammer; W J McCune; J R David
Journal:  Arthritis Rheum       Date:  1981-11

3.  Conformational states of fibronectin. Effects of pH, ionic strength, and collagen binding.

Authors:  E C Williams; P A Janmey; J D Ferry; D F Mosher
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

4.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

5.  Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network.

Authors:  J C Jennette; J Wieslander; R Tuttle; R J Falk
Journal:  Am J Kidney Dis       Date:  1991-10       Impact factor: 8.860

6.  Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic diseases as measured by 125I-radioimmunoassay.

Authors:  J M Stuart; E H Huffstutter; A S Townes; A H Kang
Journal:  Arthritis Rheum       Date:  1983-07

7.  Interaction of plasma fibronectin with selected cryoglobulins.

Authors:  G Wood; M Rucker; J W Davis; R Entwistle; B Anderson
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

8.  Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus.

Authors:  L W Moreland; R E Gay; S Gay
Journal:  Clin Immunol Immunopathol       Date:  1991-09

9.  The influence of anti-fibronectin antibodies on interactions involving extracellular matrix components and cells: a possible pathogenic mechanism.

Authors:  M S Atta; R J Powell; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

10.  Incidence and correlation between serum IgG and IgM antibodies to native type II collagen in patients with chronic inflammatory arthritis.

Authors:  R B Clague; M J Shaw; P J Holt
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

View more
  6 in total

1.  Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.

Authors:  Quan-Zhen Li; Quan Li Zhen; Chun Xie; Tianfu Wu; Meggan Mackay; Cynthia Aranow; Chaim Putterman; Chandra Mohan
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

3.  Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.

Authors:  M S Atta; K L Lim; D A Ala'deen; R J Powell; I Todd
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

4.  The influence of anti-fibronectin antibodies on interactions involving extracellular matrix components and cells: a possible pathogenic mechanism.

Authors:  M S Atta; R J Powell; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

5.  MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.

Authors:  Estefania Ugarte-Berzal; Lise Boon; Erik Martens; Vasily Rybakin; Daniel Blockmans; Jennifer Vandooren; Paul Proost; Ghislain Opdenakker
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

6.  Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome.

Authors:  Vera M Ripoll; Francesca Pregnolato; Simona Mazza; Caterina Bodio; Claudia Grossi; Thomas McDonnell; Charis Pericleous; Pier Luigi Meroni; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  J Autoimmun       Date:  2018-07-19       Impact factor: 7.094

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.